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RNA expression profiling as prognostic tool in renal patients: Several events have been put forward as essential to
Toward nephrogenomics. Damage to the kidney generally elic- the progression of renal disease. Much knowledge has
its tissue repair mechanisms, but these processes themselves been achieved from research in models for glomerulo-
conversely may result in the progression of chronic renal dis-
nephritis. Damage to the glomerulus, the tubulointerstit-ease. In a majority of patients chronic renal insufficiency pro-
ium, or both will generally lead to an influx of inflamma-gresses to a common histological end point, marked by the
tory cells, such as platelets, macrophages/monocytes, andpresence of a vast amount of scar tissue, that is, glomeruloscle-
rosis and interstitial fibrosis. These lesions are the result of an T-cells [1–3]. At this acute stage, the renal parenchyma
excessive production of extracellular matrix (ECM) compo- will attempt to repair itself. This process can be divided
nents. Studies on RNA expression in experimental kidney dis- into several stages [4]. The infiltrating cells release cyto-
ease have shown that renal mRNA levels for ECM components
kines and chemokines, factors that can activate residentand cytokines can function as prognostic tools. This suggests
fibroblasts and stimulate proliferation of renal cells.that mRNA levels potentially predict outcome and reaction to
Upon activation, fibroblasts and parenchymal renal cellstherapy in patients with renal diseases. Timely detection of
molecular alterations could allow early therapeutic interven- undergo a phenotypic change characterized by de novo
tion that slows down or even prevents the development of expression of alpha-smooth muscle actin [2], and are at
sclerotic and fibrotic lesions. This review first provides a short this stage termed myofibroblasts [5, 6]. Within the scope
introduction on mechanisms of initiation and progression of re-
of a repair mechanism, activated myofibroblasts startnal disease. Molecular techniques are available to identify renal
producing ECM [7, 8]. Resolution of the inflammatoryRNA sequences potentially involved in disease progression.
process occurs within time. However, when resolutionWe discuss several molecular techniques that are being used
in kidney research for quantitation and detection of mRNA. of the tissue damage is not accomplished in time, perpet-
This is followed by a brief overview of investigation in experi- uation of the activated state of fibroblasts will occur.
mental renal diseases, which reveal that alterations in tissue This is accompanied by a shift in the balance between
ECM mRNA levels precede histological damage and can func-
ECM synthesis and degradation [9]. During progressiontion as predictors of clinical outcome. In particular, studies in
of renal disease, ECM overproduction and reduced ECMhuman kidney biopsies that evaluate the prognostic value of
degradation lead to expansion of the extracellular ma-mRNA levels with respect to renal function are examined,
paying special attention to the pitfalls that potentially are en- trix. In addition, in some conditions modification in the
countered when interpreting the results of such studies. Then, structures of the accumulated ECM components leads to
we elaborate on ways of optimal exploitation of mRNA quanti- lower susceptibility to degradation by the regular matrix
fication as a prognostic tool. The potential and limitations of metalloproteinases (MMPs) present in the renal tissuemicroarray technology in the search for genes specifically in-
[10]. Further inappropriate accumulation of ECM leadsvolved in progression of renal disease are reviewed, including
to renal scarring, and eventually to end-stage renal fail-RNA expression profiling and large-scale DNA mutation screen-
ing. Finally, the future utilities of microarray in nephrology and ure (ESRF).
renal pathology are discussed. Progression to ESRF is influenced to a large extent by
secondary factors such as hypertension, hyperglycemia,
hyperlipidemia, and protein intake. Furthermore, the out-
Key words: mRNA quantification, prognosis, microarray technology, come of renal tissue damage depends on factors such as
kidney disease patients, tissue repair, progressive renal disease, chronic
the patient’s age and complex genetic factors. Althoughrenal insufficiency, fibrotic lesions, sclerotic lesions, DNA mutation
screening, gene search. renal diseases have diverse underlying pathogenetic
mechanisms, it has been postulated that progressive lossReceived for publication January 9, 2002
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of scarring tissue as a result of the accumulation of ECM analysis to around 20 samples at one time. The technique
of RNA in situ hybridization (RISH) is employed tocomponents seems to be the key feature of the final com-
mon pathway leading to end-stage renal disease (ESRD), localize specific mRNAs in cells or tissues. The advan-
tage of RISH over other RNA detective techniques isirrespective of the original etiology of the disease [12].
There is emerging evidence that cytokines are key that it provides information about the location of mRNA
within the renal tissue. Unlike Northern blot analysis andfactors in the development of renal disease. These com-
pounds mediate tissue remodeling and repair mechanisms, RPA, RISH does not require the isolation or electropho-
retic separation of RNA. However, it is generally ac-events that might result in increased ECM assembly and
scarring. One of the most extensively investigated cyto- cepted that this technique is not quantitative, and also
is very time-consuming and laborious.kines in the context of renal disease is transforming
growth factor-beta (TGF-) [13–18]. Other cytokines To test whether in humans the early mRNA elevation
of ECM components predicts for the development ofthought to be involved in renal diseases include platelet-
derived growth factor (PDGF), connective tissue growth chronic renal disease has proven to be a difficult task.
This is mainly due to the limited amount of biopsy tissue,factor (CTGF), fibroblast growth factor-2 (FGF-2), epi-
dermal growth factor (EGF), insulin-like growth factor-1 the difficulties in isolating intact RNA from minor quan-
tities of tissue, and the lack of both rapid and sensitive(IGF-1), several interleukins (IL), tumor necrosis factor-
alpha (TNF-), interferon-gamma (IFN-), and macro- ways of quantitative mRNA measurement in small biopsy
specimens. Since the amounts of mRNA obtained fromphage colony-stimulating factor (M-CSF). The participa-
tion of the mentioned cytokines in renal disease has been minute quantities of renal tissue in clinical practice are
below detection levels to be picked up by techniquesconfirmed by showing their presence and up-regulation
in diseased renal tissue, by the fact that their expression such as Northern blotting and RPA, investigators have
been making use of the reverse-transcriptase polymer-often correlates with that of ECM components, and by
genetic linkage analyses [19–27]. ase chain reaction (RT-PCR). Quantitative RT-PCR of-
fers a good alternative to reproducibly quantitate mRNATo identify RNA sequences that may potentially be
of value as prognostic tools in renal diseases, investiga- levels [28–30]. This technique of competitive PCR for
measuring mRNA has been widely used in animal exper-tors have made use of an arsenal of molecular techniques.
The next section provides a brief overview of some of iments and in isolated human glomeruli from native kid-
neys [31–33]. The recent development of real-time PCRthe techniques that are frequently used for measuring
RNA expression, and their general advantages and dis- is a further major contribution to rapid and reliable
mRNA measurement in small tissue specimens [34, 35].advantages are elaborated.
In comparison with the more classical molecular-biologi-
cal techniques summarized above, real-time PCR is anTECHNIQUES FOR QUANTITATION OF mRNA
attractive method of choice in terms of high sample
Northern blotting has been the standard for detection throughput. Despite this advantage, the number of tran-
and quantitation of mRNA levels. The technique is ideal scripts for which mRNA expression can be measured in
for determining transcript size and for identifying alter- one sample by real-time PCR is still limited. For several
natively spliced transcripts; however, two drawbacks of years, scientists have been making use of techniques such
the procedure are that it is laborious and time-consum- as differential display and subtractive hybridization to
ing. This is primarily due to the amount of time that is screen RNA profiles between samples, and obtain differ-
necessary for blotting the RNA on a nylon filter and for entially expressed genes. The even more recent arrival
hybridizing a specific probe to the RNA fixed on the of microarray technology offers the possibility to simul-
filter. Since Northern blotting is based on a non-ampli- taneously measure the RNA expression of thousands of
fying way of mRNA quantification, the procedure has a genes in the kidney tissue, as if one obtains the results
low sensitivity. For this reason, the technique is suitable from thousands of Northern blot experiments at the same
only for experiments in which the availability of tissue time. The potential and limitations of the microarray
is not a limiting step, for example, in animal models or technique are elaborated upon later in this article. First,
in vitro experiments. Another limitation of Northern a brief outline of experiments shows the potency of levels
blotting is the difficulty associated with analysis of multi- of mRNA as prognostic tools, both in animal models in
ple transcripts. The ribonuclease protection assay (RPA) human kidney diseases.
is a good technique for simultaneously examining mul-
tiple mRNA transcripts (10 to 15) in one sample, and is
ALTERATIONS IN mRNA LEVELS PRECEDEmore sensitive than Northern blotting. The basis of RPA
HISTOLOGICAL DAMAGEis solution hybridization of an antisense probe to an RNA
sample. RPA is even more time-consuming than North- Studies in murine chronic graft-versus-host (GvH) dis-
ease and chronic serum sickness (CSS) in the rat haveern blotting, and its complex nature in practice limits the
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particularly focused on the timing of up-regulation of
mRNA levels for ECM components in relation to accu-
mulation of the proteins and to the onset of histological
damage.
During the course of the GvH disease in the mouse,
renal mRNA levels for laminin, collagen 1(IV), and
collagen 1(I) have been studied in whole cortex and in
glomeruli. mRNA levels for these ECM components are
already increased four weeks after the induction of the
disease, and they remain elevated during the entire course
(Fig. 1A) [36]. Furthermore, during the first weeks after
induction of the disease alterations of the splicing pattern
of the V-region of fibronectin occur at the mRNA level
[37]. Six weeks after the induction of the disease, the
first signs of increased protein accumulation of the ECM
components studied are observed [38]. At this point, the
mice also start developing proteinuria. At ten weeks,
focal and segmental glomerulosclerosis is detected, with
progression to global glomerulosclerosis between ten and
twelve weeks. Further experiments showed that early
treatment, coinciding with the time frame in which up-
regulation of renal ECM mRNA levels was detected,
proved beneficial and led to prevention of glomeruloscle-
rosis [39]. Administration of cyclosporine at week 6 sup-
presses the increase of cortical collagen IV and collagen
I mRNA levels, and prevents glomerulonephritis and
glomerulosclerosis, but only in animals that are not pro- Fig. 1. Early elevation of extracellular membrane (ECM) mRNA lev-
els precedes accumulation of ECM protein and the onset of glomerulo-teinuric at that time [39].
sclerosis. Symbols are: () collagen a1(IV); () collagen a1(I); ( )In chronic serum sickness in the rat, glomerular mRNA laminin b2. Two animal models were employed: (A) graft versus host
levels for laminin, collagen 1(IV), collagen 2(IV), and (GvH) disease in mice and (B) chronic serum sickness (CSS) in rats.
During the course of the diseases, renal RNA levels for several ECMfibronectin peak at five weeks after induction of the dis-
components were measured by Northern blot analysis. These mRNAease, but mostly return to normal by week 20 (Fig. 1B) levels are already increased one month after initiation of the disease.
[40, 41]. Splicing at the V-region of fibronectin is ob- The first signs of accumulation of ECM protein and of histological
damage are detected at later stages of the disease. Data are adaptedserved in an early phase of the disease [37]. Only at
from [36, 40, 41].
twenty weeks after induction of the disease, the first
signs of ECM accumulation are detected [40]. Between
weeks 30 and 35, the kidneys show focal and segmental
in this model showed that levels of collagen 1(I) mRNAglomerulosclerosis. In conclusion, the results from these
measured at day 7 predict for the extent of fibrosis attwo animal models suggest that mRNA levels for ECM
day 30. The early mRNA levels also predict for the per-molecules may serve as prognostic tools in a way that
centage of fibrous crescents at day 30. Most importantly,changes in mRNA levels detected early in the course of
the predictive power of these mRNA levels is higherthe disease herald alterations at the protein level and
than that of serum creatinine levels, urine protein, thehistological changes occurring in later stages.
extent of glomerular damage, and the extent of intersti-
tial damage, all measured at day 7 [33].
LEVELS OF mRNA AS PREDICTORS FOR Mice transgenic for the bovine growth hormone gene
RENAL OUTCOME (bGH-tg) show rapidly progressive glomerulosclerosis,
Molecular-biological research in an animal model for whereas mice transgenic for a mutated bGH gene (bGH-
anti-glomerular basement membrane (anti-GBM) dis- m11-tg) show slowly progressive glomerulosclerosis [44].
ease and in transgenic animals has shown that early levels Between two and three months of age, the increase in
of mRNA correlate with renal outcome in a later phase glomerular mRNA levels of various cytokines and ECM
of the disease. molecules in bGH-tg mice is approximately twice as high
Already at day 4 after initiation of anti-GBM disease as that in bGH-m11-tg mice. Additional results from
in rabbits, mRNA levels of collagen 1(I), collagen experiments in normal mice [31], non-obese diabetic
mice [45], and bGH-tg mice suggest that the levels of1(IV), and TGF- are increased [42, 43]. Further study
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ECM mRNA predict the slope of progression of renal
function loss. This slope parallels the increase of ECM
mRNA [46–48].
Based on the findings in animal models, the hypothesis
was put forward that mRNA levels of ECM components
might serve as prognostic tools in patients with chronic
renal diseases. Three important features, found in animal
models, served as the basis for this hypothesis: (1) alter-
ations of mRNA levels for ECM components and ECM-
regulating cytokines are detected before a change in
ECM protein composition takes place, and before the
onset of sclerotic lesions; (2) ECM mRNA levels corre-
late with the rate of renal disease progression; and (3)
early levels of ECM mRNA correlate with the extent of
kidney damage in a later phase of the disease. Fig. 2. High transforming growth factor- (TGF-) mRNA levels dur-
ing early acute rejection are associated with absence of chronic rejec-
tion. Cortical TGF- mRNA levels were measured by real-time PCR
EVALUATION OF THE PROGNOSTIC VALUE in biopsies taken during acute rejection episodes within the first six
months after transplantation. The “progressors” group (N  10) showsOF RENAL mRNA LEVELS IN HUMANS
progressive deterioration of graft function beyond six months, and
A considerable number of studies have made use of develops chronic rejection. The “non-progressors” group (N  18)
retains a stable graft function beyond six months for at least five years.quantitative RT-PCR for measuring mRNA levels in glo-
mRNA levels are shown relative to the mean mRNA level in themerular tissue from patients in relation to diagnosis progressor group, which has been set to 1. Data are expressed as means
[49–53]. However, none of these studies have involved of duplicate measurements (P  0.05). (Reproduced with permission
from Transplantation 73:573–579, 2002.)the tubulointerstitial compartment in their analyses, or
have looked at the potential prognostic value of the
mRNA levels.
In recent years, we and others have been trying to early acute rejection within the first six months after
find an answer to the question whether mRNA levels of transplantation predict for the occurrence of chronic re-
ECM components and TGF- in biopsy tissue have a jection in a later phase after transplantation. The results
prognostic value in patients with renal diseases or re- from this study showed that during the acute rejection
nal allografts. For this purpose, first the RNA isolation episodes the mean mRNA levels for all molecules stud-
method from minute quantities of microdissected glo- ied, but in particular those for TGF- (Fig. 2), were
merular and tubulointerstitial tissue was improved (ab- higher in the non-progressors than in the progressors.
stract; Baelde HJ, J Am Soc Nephrol 12:809A, 2001) In conclusion, high mRNA levels for TGF- and ECM
[54, 55]. It was shown that mRNA quantitation is feasible molecules during acute rejection are associated with ab-
in whole cortex obtained from frozen archival biopsy sence of late chronic rejection [57].
specimens [54]. This finding corroborates frozen, archival Over the last four years we have been collecting fresh
renal tissue as an important source for obtaining proper biopsy tissue from renal patients who are under clinical
RNA in future kidney research. In subsequent studies, surveillance in our hospital center or in surrounding hos-
mRNA levels for collagen IV and collagen I proved to pitals. Each biopsy was microdissected under stereo-
be age-dependent in kidneys without any signs of renal microscopy to separate glomeruli and tubulointerstitium.
disease [56]. In addition, mRNA levels in a renal biopsy RNA was isolated from both compartments. Real-time
specimen turned out to be representative of those in the PCR was applied on microdissected biopsy tissue from
entire kidney [56]. These observations are to be taken 52 patients with various renal diseases for the measure-
into account when ECM mRNA levels are used for diag- ment of mRNA levels for TGF-, collagen IV, collagen
nostic purposes. In a recent study, the RNA isolation I, and fibronectin. The glomerular filtration rate (GFR)
technique and real-time PCR method were used to mea- was determined at the time of biopsy and was followed
sure mRNA levels of TGF-, collagen IV, collagen I, for one year. The goal was to determine the predictive
and decorin in archival tissue from 28 patients with a value of the mRNA levels for the rate of change in renal
renal transplant [abstract; Eikmans M et al, J Am Soc function of the patients after biopsy (abstract; Eikmans
Mephrol (in press)]. Eighteen patients retained stable M, J Am Soc Nephrol 12:70A, 2001). The predictive power
graft function for at least five years (non-progressors), of the mRNA levels was compared to that of functional
whereas 10 patients lost their grafts to chronic rejection parameters and the extent of histological damage at time
within this period of time (progressors). The main ques- of biopsy. The findings show that tubulointerstitial TGF-
mRNA levels and glomerular fibronectin mRNA levelstion was whether the mRNA levels measured during
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correlate with the rate of change in renal function be- OPTIMAL EXPLOITATION OF mRNA LEVELS
AS PROGNOSTIC TOOLStween time of biopsy and one month, and between three
months and 12 months, respectively [abstract; Eikmans M There are some drawbacks in the light of efforts to use
et al, J Am Soc Nephrol (in press)]. Thus, relatively high tissue mRNA levels as prognostic tools. First, a kidney
mRNA levels for TGF- and fibronectin are associated biopsy is generally taken because of renal dysfunction.
with a relatively favorable prognosis. Most often, renal biopsies obtained from patients with
renal diseases already contain histological abnormalities
to such an extent that, even if mRNA levels should beTHE ROLE OF TGF-
of any prognostic value, therapeutic intervention is only
An interesting, but controversial, result obtained from expected to be partially effective at best. In contrast,
the studies described above is that relatively high mRNA research in animal models theoretically allows analysis
levels for TGF- and ECM components are associated of mRNA levels over the entire period of disease pro-
with a relatively favorable prognosis with respect to renal gression. In this case, the detection of early alterations
function of native kidneys and transplanted kidneys. The at the mRNA level allows the prevention of sclerosis by
controversial aspect in this finding lies in the fact that therapeutic intervention in an early phase of the disease
in the literature primarily the role of TGF- in renal [39]. Our study mentioned earlier performed in 52 pa-
scarring has been emphasized. It has been postulated tients with diverse renal diseases included almost exclu-
that overproduction or persistent production of TGF- sively patients who had been suffering from clinical
leads to excessive deposition of ECM components, and symptoms already for some time. To render mRNA anal-
eventually to scarring of renal tissue [16, 17, 58, 59]. ysis even more effective as a prognostic tool, it would
At the same time, it has been recognized that TGF- be ideal to measure mRNA levels in biopsies with normal
can exert anti-inflammatory effects and plays an impor- histology, or at least without chronic lesions.
tant role in regulation of tissue repair and regeneration Secondly, the patients in our studies already received
after tissue injury. We hypothesize that the beneficial appropriate medication according to standard protocols
actions of TGF- such as its anti-inflammatory actions [abstract; Eikmans M, J Am Soc Nephrol 2000 (in press)]
or its role in tissue repair explain our findings. Firstly, [57]. If accurate, the prediction of who eventually will
TGF- has been shown by several investigators to exert progress toward chronic damage and who will not by
anti-inflammatory effects [60, 61], and more specifically means of mRNA detection would allow for more inten-
it has been shown to inhibit B cells, T helper cells, cyto- sive follow-up of patients at risk for progression, and
toxic T cells, and macrophages [62, 63]. Secondly, TGF- the use of more aggressive medication during the pre-
regulates ECM expression in relation to tissue repair sclerotic stage to prevent the development of sclerosis
and remodeling [64]. and fibrosis. The application of TGF- inhibitors as a mo-
Some additional comments on potential pitfalls in the lecular approach to intervene early in the development
studies described above have to be made. The mRNA of renal disease, as it was successfully used for attenua-
levels determined in the biopsies are likely under the tion of glomerulonephritis in rats [65], at the moment
influence of many variables, including the type and dose seems to be questionable in human renal disease. The
of medication, the time of biopsy, and in the case of the studies in patients with renal transplants raise the ques-
transplantation study, the severity of the acute rejection. tion whether it would be beneficial, in any stage of acute
Therefore, valuable information would be gained if all allograft rejection, to inhibit the actions of TGF- [57].
biopsies taken within the first six months after trans- Using mRNA levels as prognostic tools would require
plantation, and the pre-transplant biopsy from each pa- a baseline measurement in biopsies taken before the
tient were studied. This would establish in a single patient onset of any renal scarring whatsoever. A way to tackle
the amount of variation in mRNA levels between differ- this issue would be to perform mRNA measurements in
ent acute rejection episodes. To test the hypothesis that protocolized biopsies, for example in patients with a re-
TGF- acts as an immunosuppressant during acute rejec- nal allograft at times of stable renal function, or in pa-
tion, an analysis of the composition of cellular infiltrates tients with systemic diseases [for example, diabetes, sys-
in biopsies in relation to TGF- expression levels would temic lupus erythematosus (SLE), vasculitis] in early
be clarifying. In addition, analysis of TGF- and the stages or remission. To predict the development of dia-
ECM components at the protein level by immunohisto- betic nephropathy, one could consider performing mRNA
chemistry would certainly be informative. Finally, the measurements in biopsies from individuals with diabetes
possibility should be taken into account that the presence mellitus, having only microscopic albuminuria. At this
of high TGF- mRNA levels reflects a higher respon- stage, the biopsy is not expected to show histological
siveness to therapy, and thus a better prognosis in the abnormalities, and the mRNA levels measured in the
tissue may be used to identify the individuals at risk oflong term.
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developing diabetic nephropathy. In this respect, a re- from patients with congenital nephrotic syndrome [74].
Much has been speculated about the recent developmentcent study by Adler and colleagues of mRNA quanti-
tation in biopsy specimens from patients with type I of the microarray technique that allows screening of the
complete human genome at the mRNA level in one sin-diabetes is worth mentioning [66]. Whereas glomerular
mRNA levels of collagen IV and CTGF are twofold gle experiment [75–77]. This includes the use of custo-
mized or commercially produced cDNA microarray chips.higher in microalbuminuric patients compared to normo-
albuminuric patients, the degree of glomerular mesangial The former allows the analysis of smaller subsets of genes
within certain fields of research. This was recently de-expansion between the two patient groups did not sig-
nificantly differ. It would be interesting to see if the scribed in studies that used arrays containing 250 toxicity-
related genes [78], and cDNA microarray for expressionlevels of mRNA within the microalbuminuric group are
associated with the rate of change in renal function or profiling of inflammation-associated genes [79]. With
commercially produced microarray chips, approximatelyproteinuria after biopsy.
A third drawback when attempting to use tissue 22,000 sets of cDNA molecules, each encoding for a dif-
ferent gene, are printed on an array the size of a thumb-mRNA levels as prognostic tools is that taking a renal
biopsy is an invasive procedure that is uncomfortable for nail. The RNA is extracted from the kidney tissue, la-
beled with a fluorescent dye, and allowed to hybridizethe patient and occasionally results in a life-threatening
complication. Implementation of protocolized biopsies with the cDNA printed on the array. Thus, the amount
of RNA hybridized to the array can be used as a measurein clinical practice therefore brings along an additional
risk for the patient, and it also may result in ethical and, for the amount of mRNA of singular transcripts present
in the RNA sample. Analysis and management of mi-possibly, economic objections. This is the major reason
why several research groups investigate the potential croarray data are currently difficulties in application of
the technology. This includes gene clustering and predic-diagnostic and prognostic value of mRNA levels deter-
mined using noninvasive tests, for example, by perform- tion of gene function [80, 81].
More recently, microarray technology was used toing measurements of mRNA in the urine or in the cir-
culation [67, 68]. However, there is some skepticism identify specific gene expression patterns in various types
of tissues other than renal cortex as well. Classificationconcerning such applications. In particular, the question
remains whether these non-invasive tests are as reliable of subsets of tumors on the basis of RNA expression
profiles might have major implications for assessing prog-as measurements in a renal biopsy in terms of specificity
in relation to the renal disease. nosis and establish medication tuned to the individual
patient. For example, large-scale gene expression profil-
ing has been used in diagnostic tumor specimens fromAPPLICATION OF MICROARRAY
patients with diffuse large B-cell lymphoma [82]. A smallTECHNIQUES FOR RNA PROFILING
subset of genes was differentially-expressed between pa-
The simultaneous RNA expression analysis of a large tients with a relatively favorable prognosis and those with
number of genes is a logical step in elucidating the molec- a relatively unfavorable prognosis. These so-called marker
ular mechanism that underlies disease initiation and pro- genes predicted clinical outcome better than histological
gression. After all, it has been shown in animal models alterations in the tissue. Another example is the use of
that quantitative changes at the RNA level precede and microarray in identifying high-risk breast cancer patients.
predict changes at the protein level. The identification In a large group of patients with a breast tumor, a subset
of specific genes involved in the onset and progression of of marker genes predicted a high risk of relapse of the
renal disease may in the end reveal the most appropriate disease and the occurrence of distant metastases [83].
molecular target for drug intervention.
To study RNA expression profiles in renal cells or
SCREENING OF DNA MUTATIONS ANDtissue at a large scale, investigators have made use of tech-
GENE POLYMORPHISMSniques such as cDNA subtractive hybridization, mRNA
differential display, and high-density cDNA filter array. In a number of diseases including kidney disorders,
mutations occurring in the DNA have important implica-Extensive research has focused on the mapping of RNA
expression profiles with regard to the development of tions for prognosis and therapy. Techniques such as re-
striction fragment length polymorphism (RFLP) and sin-diabetic nephropathy, in order to find genes that poten-
tially are involved in this process [69–71]. In these studies, gle-strand conformation polymorphism (SSCP) have been
used for detection of genetic alterations. The screeningexperimental models for diabetes and cell cultures stimu-
lated with high glucose concentrations were used. With of all possible mutations in one gene using such ap-
proaches is mostly cumbersome. The use of microarraysimilar molecular techniques, gene expression profiles
have been obtained in normal human renal cortex [72], technology for large-scale screening of mutations and
gene polymorphisms might be the solution, and this hasin patients with IgA nephropathy [73], and in glomeruli
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already been initiated in cancer research. Mutations in of studies in renal biopsy tissue in terms of restriction
of inconvenience for the patient and timing of sampling.the BRCA1 gene may place individuals at risk of devel-
oping breast and ovarian cancer. High-density arrays con-
sisting of over 96,000 oligonucleotides were employed FUTURE UTILITIES OF MICROARRAY
to screen for heterozygous mutations in BRCA1 [84]. TECHNOLOGY IN NEPHROLOGY:
Another example is the employment of microchip analy- TOWARD NEPHROGENOMICS
sis for mutation screening in patient samples in the cystic
In kidney research, microarray gene profiling mightfibrosis gene [85].
be used in similar ways as currently performed in cancerIndividual profiling of DNA patterns also might be an
research. Simultaneous RNA expression profiling ofapproach to the identification of individuals at risk for
thousands of genes in biopsy tissue from patients withdeveloping progressive renal disease. It is generally be-
kidney diseases might identify shared gene expressionlieved that a genetic component is involved in the devel-
patterns involved in development and progression ofopment of many renal diseases. Several examples in
renal disorders. This eventually opens the way to aimedwhich mutations in a single gene or a chromosome region
therapy for the individual patient. Currently a limitationlead to renal dysfunction have appeared recently in the
of the microarray technique is that still relatively large
literature. For instance, mutations in the NPHS1 gene
amounts of RNA, in general at least 10 g, are needed
are the cause of the congenital nephrotic syndrome [86]. for hybridization. In cancer research, the tumor samples
This autosomal recessive disorder is accompanied by the from patients are often large enough for obtaining indi-
absence of nephrin from the slit pore diaphragm of the vidual expression profiles by array analysis. However,
kidney [87], and, consequently, by the presence of heavy the yield of RNA from renal specimens is considerably
proteinuria. Both for IgA nephropathy and diabetes mel- lower than the amount of RNA needed for hybridization
litus, the most common causes worldwide of progressive on current arrays. At the moment, this excludes the pos-
renal failure leading to ESRD, a genetic component has sibility of application of microarray in individual renal
been described. Familial IgA nephropathy was linked patients. Recent breakthroughs in nanotechnological re-
to chromosome 6 [88]. Two chromosome regions show search may enable the use of even smaller array chips
association with, and linkage to type I diabetes: the HLA in the near future, which need far less RNA for proper
region and the insulin region [89]. The application of hybridization than the current microarray chips [98, 99].
microarray technology, especially in individuals from One solution to the problem that a singular biopsy
families in which renal diseases occur frequently, could specimen contains too little RNA for a microarray exper-
be useful in the detection of specific gene mutations that iment would be pooling the RNA from multiple biopsies.
may lead to progressive renal disease. Currently, experiments are on the way using the microar-
In the past years, investigation of single nucleotide ray technique on RNA obtained from diseased native
polymorphisms (SNPs) in relation to disease occurrence and transplanted kidneys. As an example, Figure 3 shows
and susceptibility has gained considerable attention. One the hybridization signals of two patient groups having a
can think of the occurrence of gene polymorphisms in the renal transplant. RNA was obtained from renal allograft
DNA leading to alterations of amino acids, and thereby biopsies from patients with acute rejection within six
in altered functionality of the gene protein product. In months after transplantation. Part of the patients pro-
addition, polymorphisms in the promoter region of a gressed to chronic rejection within a few years (pro-
gene might have influence on the rate of mRNA tran- gressors), whereas the other patients retained a stable
scription of this gene. In renal allografts, gene polymor- graft function during the same time period (non-pro-
phism in the proinflammatory cytokines TNF- and IL-10 gressors). To identify differentially expressed genes be-
has been associated with the occurrence of acute rejec- tween progressors and non-progressors, microarray anal-
tion [90]. Similarly, genotypic variations in the TGF- ysis was performed on pooled RNA samples from the
gene have been described in relation to the occurrence of two patient groups (Fig. 3). The red and blue dots that lie
renal failure [91–93]. Polymorphisms in the angiotensin I the furthest from their corresponding cluster represent
gene and angiotensin-converting enzyme gene have been RNA encoding for molecules that are differentially ex-
characterized in relation to progression of renal disease pressed between the two samples. These molecules are
[94–97]. Microarray techniques might be suitable for of particular interest, since they might play a role in
large-scale screening of SNPs in candidate genes ana- progression of allograft damage. The results of this study
lyzed in DNA extracted from blood samples of patients will be described in detail in a forthcoming paper (Eik-
with renal diseases. SNP analysis could be performed mans et al, manuscript in preparation).
with the aid of probes hybridizing to relatively short We envision that the results from genetic linkage anal-
oligonucleotides printed on the arrays. The fact that such yses in families with hereditary kidney disease, and from
microarray application on bulk amounts of kidney tissueanalyses can be done in blood samples is to the advantage
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Fig. 3. Microarray analysis of approximately 12,000 genes in renal transplant biopsies with acute rejection. RNA was pooled from biopsies obtained
from two groups of at least ten patients One group of patients eventually develops chronic rejection within a few years (A; progressors). The
other group retains a stable graft function for at least five years (B; non-progressors). A and B show part of the arrays after hybridization and
scanning for both patient groups. (C ) Each dot in the graph represents the hybridization signal of a single gene. The horizontal and vertical axes
depict the intensity (logarithmic scale) of the genes in the progressor and non-progressor groups, respectively. Yellow dots: intensity is below
threshold level in both groups. Blue dots: intensity is below threshold level in one of the groups. Red dots: high intensity in both groups.
from single cases or on pooled samples from multiple the practical procedure of the technique itself, but rather
the interpretation and processing of the data. One needscases will cut back the number of key genes involved in
the development of kidney disease. This will eventually to be cautious not to drown in the amount of data gener-
ated from experiments with microchips. It is temptinglead to the development of designer chips containing a
limited set of kidney disease-specific candidate genes, to interpret the microarray data within an established
framework of current knowledge from nephrological re-which need further testing in large patient groups. At
the same time, one could think of performing in DNA search, focusing especially on genes that already have
been described in literature to play a role in renal disease.samples large-scale SNP analyses of candidate genes that
previously have come up in the microarray analyses on Rather, of particular interest are those genes that appear
at the top of the list, despite the fact that they at firstthe basis of their RNA expression. The very challenge
at the moment in microarray application is not so much seem inexplicable in relation to renal pathology. Such
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Nephrology in 2001, Dr. M. Eikmans received the Young Investigatorgenes need to be further tested for their plausibility by
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databases could identify specific molecular pathways in-
volved in renal pathology, establishing specific molecular APPENDIX
targets for drug intervention in kidney disease.
Abbreviations used in this article are: CSS, chronic serum sickness;
CTGF, connective tissue growth factor; ECM, extracellular matrix;
EGF, epidermal growth factor; ESRD, end-stage renal disease; ESRF,
CONCLUSION end-stage renal failure; FGF, fibroblast growth factor; GBM, glomeru-
lar basement membrane; GvH, graft versus host; IGF-1, insulin-likeProgression of chronic renal disease is associated with
growth factor-1; M-CSF, macrophage colony-stimulating factor; MMP,
a decrease in renal function and an accumulation of matrix metalloproteinase; mRNA, messenger RNA; PDGF, platelet-
derived growth factor; RFLP, restriction fragment length polymor-ECM components, directed by the actions of cytokines.
phism; RISH, RNA in situ hybridization; RPA, ribonuclease protectionInvestigators have been making use of different molecu-
assay; RT-PCR, reverse transcription-polymerase chain reaction; SLE,
lar techniques to measure mRNA expression levels in systemic lupus erythematosus; SNP, single nucleotide polymorphism;
SSCP, single strand conformation polymorphism; TNF-, tumor necro-renal tissue, each with their own advantages and limita-
sis factor-; TGF-; transforming growth factor-.tions. Experiments in animal models show that mRNA
levels for ECM components can be used to predict renal
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